1681017-83-3
Chemical Structure
Venadaparib
Synonym(s): IDX-1197
- CAS No.: 1681017-83-3
- Formula:C23H23FN4O2
- Molecular Weight:406.45
IUPAC Name: 4-(3-(3-((cyclopropylamino)methyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
InChIKey: YNBQAYKYNYRCCA-UHFFFAOYSA-N
SMILES: O=C1NN=C(CC2=CC=C(F)C(C(N3CC(CNC4CC4)C3)=O)=C2)C5=C1C=CC=C5
Biological Activity: Venadaparib (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib does not sensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSB) and can be used for solid tumors research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Venadaparib | 98.52% | Venadaparib (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib does not sensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSB) and can be used for solid tumors research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.99
HY-137457AVenadaparib hydrochloride -
Similarity Score 0.77
HY-13536AZD-2461 -
Similarity Score 0.76
HY-136489KU-0058948 -
Similarity Score 0.76
HY-75706N-Descyclopropanecarbaldehyde Olaparib -
Similarity Score 0.76
HY-136489AKU-0058948 hydrochloride -
Similarity Score 0.74
HY-10162Olaparib -
Similarity Score 0.69
HY-156982Parpi -
Similarity Score 0.68
HY-10162S3Olaparib-d4-1 -
Similarity Score 0.66
HY-179208N-Descyclopropanecarbaldehyde Olaparib suberic acid -
Explore the MedChemAI to find more analogs
References
- [1]. Myongjae Lee, et al. Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor. American Association for Cancer Research, 2018.
- [2]. Yong Man Kim, et al. First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 39, no. 15_suppl (May 20, 2021) 3107-3107.
